Women and Heart Disease The Role of Diabetes and Hyperglycemia Elizabeth Barrett-Connor, MD; Elsa-Grace V. Giardina, MD; Anselm K. Gitt, MD; Uwe Gudat, MD; Helmut O. Steinberg, MD; Diethelm Tschoepe, MD Arch Intern Med. 2004;164:934-942.
paradox that a high-fat, high–saturated fat diet is associated with diminished coronary artery disease progression in women with the metabolic syndrome, a condition that is epidemic in the United States. This paradox presents a challenge to differentiat
Surgery does not deal with the basic molecular foundation of disease. It is a mechanical approach to a biologic problem. For those of us who are considered experts in the areas of coronary disease, what an embarrassment to admit that coronary artery disea
The morbidity, mortality, expense and transient benefits of a high technology approach toward the coronary disease epidemic, has failed. It is time to realize that the answer to a faulty lifestyle epidemic is not drugs and technology – it is lifestyle.
Modern cardiology has given up on curing heart disease. Its aggressive interventions-- coronary artery bypass graft, atherectomy, angioplasty, and stenting--do not reduce the frequency of new heart attacks or prolong survival except in small subsets of pa
An unreasonable gap exists between medical enthusiasm devoted to acute interventions and meager efforts devoted to secondary prevention. Rene C. Favaloro, MD, Pioneer of Coronary Artery Bypass Graft Surgery
elective PTCA of totally occluded coronary arteries is feasible but the primary success rate is lower (57%) than that associated with conventional lesions. The long-term clinical results following successful angioplasty are satisfactory (64%), but the inc
Our patient exemplified the challenges involved in a CTO, which included the length of the lesion, the lack of a proximal nipple, the presence of a side branch at the occlusion point, poor visualization of the distal vessel despite contralateral injection
Drug-eluting stents (DES) have gained widespread adoption being implanted in over 6 million patients worldwide demonstrating significant improvements in clinical efficacy combined with comparable safety to bare metal stents.
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
B. Bruneau, G. Nemer, J. Schmitt, F. Charron, L. Robitaille, S. Caron, D. Conner, M. Gessler, M. Nemer, C. Seidman and 1 other author(s). Cell, 106 (6):
709-21(September 2001)Bruneau, B G Nemer, G Schmitt, J P Charron, F Robitaille, L Caron,
S Conner, D A Gessler, M Nemer, M Seidman, C E Seidman, J G S10 RR14792/RR/NCRR
NIH HHS/United States Research Support, Non-U.S. Gov't Research Support,
U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. United
States Cell Cell. 2001 Sep 21;106(6):709-21..